Charles River (CRL) Laboratories announced an enhanced In Vitro Fertility service bundle designed to accelerate rat-model programs across therapeutics areas, including oncology, neurology, cardiology, and metabolic. By leveraging embryo transfer, cryopreservation, and colony rederivation, teams can rapidly recover lines, expand cohorts, and safeguard critical genotypes-while reducing downtime caused by breeding bottlenecks. This offering pairs dedicated project management with optional health monitoring and genetic validation to help ensure continuity across discovery, pharmacology, and translational studies. Researchers working in these therapeutic areas can request a streamlined quote and timeline starting this quarter to keep studies on track and data flowing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River reports results of restrospective analysis on VCGs in toxicology
- Tesla upgraded, AppLovin initiated: Wall Street’s top analyst calls
- Charles River price target raised to $210 from $200 at Barclays
- Charles River initiated with an Outperform at RBC Capital
- Charles River price target lowered to $160 from $165 at JPMorgan